Abstracts

INCREASED IMMUNE ACTIVATION AND EXHAUSTION IN VERTICALLY HIV-1–INFECTED YOUNG ADULTS

Vertically HIV-infected children show irreversible immune damage associated with HIV-1 infection and early antiretroviral treatment (ART) exposure. The objective of the study is to assess immune activation and senescence of vertically HIV-infected patients once they reach adulthood compared to non-HIV-infected subjects Vertically HIV-infected group (HIV n=32) under suppressive ART for at least 5 years were…

AUTOLOGOUS INFANT ADCC RESPONSES CORRELATE WITH LOWER MTCT AND BETTER OUTCOMES

Previous studies have shown that neutralizing antibody (nAb) responses do not account for the lack of HIV-1 transmission from infected mothers to their breastfed infants. We hypothesize that antibodies capable of inducing antibody-dependent cellular cytotoxicity (ADCC) associate with decreased mother-to-child-transmission and correlate with improved outcomes in infected infants. ADCC responses were assessed using an infection-based…

DOLUTEGRAVIR AND VIRAL LOAD SUPPRESSION AMONG PEDIATRIC PATIENTS IN CARE IN ZAMBIA

Preliminary results from the ODYSSEY trial led to FDA approval for the use of Dolutgravir (DTG) in treatment-naïve or experienced young children .Previous research, predominately in well-resourced settings, has demonstrated improved efficacy, tolerability and durability of DTG when compared to other first-line antiretroviral therapy (ART) regimens. Here we assess viral suppression among pediatric patients ?18…

SWITCHING EFAVIRENZ TO RILPIVIRINE IN VIROLOGICALLY SUPPRESSED ADOLESCENTS WITH HIV

Efavirenz (EFV) based-antiretroviral therapy (ART) is commonly used for first-line treatment in adolescents and children with HIV but is associated with neuropsychiatric and metabolic side effects. Rilpivirine (RPV) has a more favorable tolerability profile and switching EFV to RPV in virologically suppressed adults was safe and ef?cacious, but data in adolescents are limited. Open-label, single-arm,…

IMPAACT 2014 24-WEEK PK AND SAFETY OF DORAVIRINE/3TC/TDF IN ADOLESCENTS WITH HIV-1

Doravirine (DOR) is a novel non-nucleoside reverse transcriptase inhibitor (NNRTI) active against both wild-type HIV-1 and the most common NNRTI-resistant variants. DOR, alone or as a fixed dose combination (FDC) of DOR/lamivudine (3TC)/tenofovir disoproxil fumarate (TDF), is approved for treatment in antiretroviral-naïve and virologically-suppressed adults with HIV-1 infection. IMPAACT 2014 investigated the pharmacokinetics (PK) and…